Display options
Share it on

J Am Heart Assoc. 2012 Jun;1(3):e001511. doi: 10.1161/JAHA.112.001511. Epub 2012 Jun 22.

Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation.

Journal of the American Heart Association

Balaji K Tamarappoo, Benjamin T John, Kyndaron Reinier, Carmen Teodorescu, Audrey Uy-Evanado, Karen Gunson, Jonathan Jui, Sumeet S Chugh

Affiliations

  1. Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (B.K.T., B.T.J., K.R., C.T., A.U.-E., S.S.C.) ; Cleveland Clinic Foundation, Cleveland OH (B.K.T.).

PMID: 23130141 PMCID: PMC3487319 DOI: 10.1161/JAHA.112.001511

Abstract

BACKGROUND: Concentric left ventricular hypertrophy (LVH) is independently associated with increased risk of sudden cardiac death (SCD). Some animal models of LVH display specific alterations of the myocardial interstitium that could increase myocardial vulnerability to ventricular arrhythmias, but these merit evaluation in humans with LVH and SCD.

METHODS AND RESULTS: Twelve consecutive patients with isolated LVH and SCD (LVH+SCD) in the absence of hypertrophic cardiomyopathy, coronary disease, or other cardiac structural abnormality were ascertained in the Oregon Sudden Unexpected Death Study. Detailed postmortem comparisons were conducted with 18 controls who had isolated LVH and unnatural deaths (Control Group A) and 6 controls who had structurally normal hearts and unnatural deaths (Control Group B). Postmortem left ventricular myocardial sections were obtained for measurement of collagen volume fraction, characterization of gap junctions, and quantification of collagen subtypes. Heart weight normalized to body weight was higher in LVH+SCD cases (6.9±1.2 g/kg) than in Control Group A (5.3±1.4 g/kg) and Control Group B (4.2±0.3 g/kg); P=0.001. Collagen volume fraction was also higher in LVH+SCD cases (3.1±0.4) than in Control Group A (2.3±0.4) and Control Group B (1.6±0.3); P=0.0002. The relative amount of collagen III was significantly higher in LVH+SCD cases (33.0±4.4%) than in Control Group A (20.9±4.3%) and Control Group B (13.4±3.5%); P=0.0001. There was an overall increase in the number of connexin 43-labeled gap junctions with increasing myocyte size. No subject was found to have high-risk hypertrophic cardiomyopathy mutations.

CONCLUSIONS: In addition to the expected increase in myocardial mass and overall collagen content, SCD with isolated LVH was associated with relative abundance of type III collagen, a novel finding that warrants further mechanistic evaluation. (J Am Heart Assoc. 2012;1:e001511 doi: 10.1161/JAHA.111.001511.).

Keywords: collagen; death, sudden; hypertrophy; myocardium; remodeling

References

  1. Am J Med. 1984 Jul;77(1):18-22 - PubMed
  2. Am J Pathol. 1989 Nov;135(5):771-81 - PubMed
  3. Pacing Clin Electrophysiol. 1997 Feb;20(2 Pt 2):397-413 - PubMed
  4. Circulation. 1993 Sep;88(3):864-75 - PubMed
  5. Br Heart J. 1986 Jun;55(6):575-81 - PubMed
  6. Heart Rhythm. 2004 Jul;1(2):141-9 - PubMed
  7. J Clin Invest. 2007 Mar;117(3):568-75 - PubMed
  8. Am J Physiol. 1999 Jul;277(1):C1-9 - PubMed
  9. Mayo Clin Proc. 1988 Feb;63(2):137-46 - PubMed
  10. Physiol Rev. 1999 Jan;79(1):215-62 - PubMed
  11. Circulation. 1998 Jun 9;97(22):2230-6 - PubMed
  12. J Am Coll Cardiol. 1991 May;17(6):1277-82 - PubMed
  13. J Am Coll Cardiol. 1998 Nov;32(5):1454-9 - PubMed
  14. Circulation. 2000 Aug 8;102(6):649-54 - PubMed
  15. Nat Rev Cardiol. 2010 Jun;7(6):318-26 - PubMed
  16. Am Heart J. 2000 Dec;140(6):848-56 - PubMed
  17. Int J Biochem Cell Biol. 2007;39(4):666-71 - PubMed
  18. N Engl J Med. 1987 Sep 24;317(13):787-92 - PubMed
  19. Cardiovasc Res. 1997 Jun;34(3):439-44 - PubMed
  20. Am J Physiol Heart Circ Physiol. 2001 Aug;281(2):H903-14 - PubMed
  21. J Hypertens. 1998 Jul;16(7):1031-41 - PubMed
  22. Am Heart J. 1992 Jan;123(1):89-95 - PubMed
  23. Eur Heart J. 1993 Nov;14 Suppl J:12-4 - PubMed
  24. Circulation. 1991 Jun;83(6):1849-65 - PubMed
  25. Circulation. 2010 Nov 30;122(22):2335-48 - PubMed
  26. Heart. 1998 Dec;80(6):548-58 - PubMed
  27. Circ Res. 1994 Aug;75(2):296-303 - PubMed
  28. Am J Hypertens. 1994 Jan;7(1):52-8 - PubMed
  29. Circulation. 1977 May;55(5):686-702 - PubMed
  30. J Mol Cell Cardiol. 1997 Oct;29(10):2837-48 - PubMed
  31. Prog Cardiovasc Dis. 2008 Nov-Dec;51(3):213-28 - PubMed
  32. N Engl J Med. 1995 Apr 20;332(16):1058-64 - PubMed
  33. Curr Opin Cardiol. 2000 Jul;15(4):264-72 - PubMed
  34. Am J Cardiol. 1987 Sep 1;60(7):560-5 - PubMed
  35. Cardiovasc Res. 2001 Aug 1;51(2):217-29 - PubMed
  36. Cardiology. 1992;81(4-5):266-73 - PubMed
  37. Eur Heart J. 1993 Jul;14 Suppl D:16-21 - PubMed
  38. Circulation. 1995 Mar 1;91(5):1450-6 - PubMed
  39. Cardiovasc Res. 2000 May;46(2):250-6 - PubMed
  40. Cardiovasc Res. 1983 Jan;17(1):15-21 - PubMed
  41. Heart Rhythm. 2011 Aug;8(8):1177-82 - PubMed
  42. Br J Pharmacol. 2004 Sep;143(2):285-91 - PubMed
  43. Circ Res. 1988 Apr;62(4):757-65 - PubMed
  44. J Mol Cell Cardiol. 2002 Oct;34(10):1273-8 - PubMed
  45. Circ Res. 1990 Dec;67(6):1474-80 - PubMed

Publication Types

Grant support